Johnson & Johnson has been ordered to pay $8bn after claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, sending the stock down by 2 per cent in after-hours trading.
The world’s largest pharmaceutical company must pay the punitive damages to
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
